NOSA.ST Nosa Med AB
- Market cap
- SEK 111M
- P/E
- -
- P/B
- 2.90x
- ROE
- -16.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NOSA.ST undervalued?
Graham numberThe Graham number of Nosa Med AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nosa Med AB fundamental analysis
No fundamental analysis for Nosa Med AB yet.
Nosa Med AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nosa Med AB
Nosa Plugs AB (publ), a medical technology company, develops, manufactures, and sells intranasal breathing products in Sweden, Europe, North America, Oceania, and internationally. It offers NOSA smell training, a smell training medical device to improve the sense of smell for individuals with parosmia and hyposmia; NOSA odor control, which reduces bad odor; NOSA microbial control that reduces the exposure of viruses and bacteria by inhalation through the nose; NOSA Nozoil or…
Full company profileNosa Med AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nosa Med AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 248K | 5.26M | 1.94M | 1.37M | 5.85M | 6.85M | 10.4M | 16.1M | 23.9M | 34.1M |
| Gross Profit | -100K | -32.5M | -47.4M | -74.5M | -104M | -6.45M | -13.6M | 6.92M | 11.2M | -8.03M | -7.77M |
| Operating Income | -24.2M | -32.5M | -47.4M | -74.5M | -104M | -6.45M | -13.8M | -46.5M | -10.3M | -8.03M | -7.77M |
| EBITDA | -24.1M | -29.6M | -37.8M | -69.6M | -179M | -38.6M | -7.68M | -45.0M | -8.16M | -4.12M | -1.07M |
| Net Income | -18.3M | -24.9M | -42.0M | -73.8M | -229M | -58.6M | -17.8M | -46.6M | -10.2M | -8.04M | -6.18M |
| EPS | -1.22 | -1.43 | -2.09 | -2.98 | -7.22 | -1.22 | -0.29 | -0.29 | -0.05 | -0.03 | -0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 172M | 200M | 215M | 204M | 116M | 40.1M | 21.7M | 33.1M | 20.7M | 64.7M | 62.5M |
| Total Liabilities | 3.60M | 7.49M | 14.2M | 15.8M | 14.6M | 980K | 3.33M | 6.33M | 4.14M | 23.7M | 24.3M |
| Shareholders' Equity | 168M | 192M | 200M | 188M | 102M | 39.1M | 6.70M | 26.8M | 16.6M | 41.1M | 38.2M |
| Cash & Short-term Investments | 41.5M | 42.5M | 41.9M | 26.7M | 87.8M | 10.4M | 2.52M | 1.19M | 4.31M | 17.3M | 16.1M |
| Total Debt | - | - | - | 6.80M | 3.28M | 9.04M | 1.72M | 1.88M | 1.01M | 716K | 1.77M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -23.5M | -27.8M | -35.1M | -52.7M | -70.0M | -6.21M | -6.93M | -17.5M | -10.0M | -6.40M | -544K |
| Capital Expenditure | 5.79M | 16.1M | 15.5M | 20.1M | 9.19M | 10.6M | 61.0K | 855K | 4.62M | 6.40M | 544K |
| Free Cash Flow | -29.3M | -43.9M | -50.6M | -72.8M | -79.1M | -16.8M | -5.19M | -18.4M | -14.7M | -6.59M | -544K |
| Ratios | |||||||||||
| ROE | -10.9% | -13.0% | -21.0% | -39.3% | -225.4% | -149.8% | -266.0% | -174.0% | -61.4% | -19.6% | -16.2% |
| ROA | -10.7% | -12.5% | -19.6% | -36.2% | -197.1% | -146.1% | -82.3% | -140.7% | -49.1% | -12.4% | -9.9% |
| Net Profit Margin | - | -10,037.9% | -799.5% | -3,810.1% | -16,760.4% | -1,000.4% | -260.2% | -447.9% | -63.1% | -33.6% | -18.1% |
| Debt to Equity | - | - | - | 0.04x | 0.03x | 0.23x | 0.26x | 0.07x | 0.06x | 0.02x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nosa Med AB dividends
Nosa Med AB has not paid dividends in the last 9 fiscal years.
Who owns Nosa Med AB
- Insiders 11.06%
- Institutions 22.64%
- Public & others 66.30%
- Shares outstanding 260M
- Free float 222M
Nosa Med AB company profile
- Company name
- Nosa Med AB
- Ticker
- NOSA.ST
- ISIN
- SE0006994539
- Exchange
- Stockholm Exchange
- Sector
- Healthcare
- Industry
- IT Services
- Employees
- 7
- Fiscal year end
- December
- Address
- Surbrunnsgatan 42, Stockholm, Sweden, 113 48
- Phone
- 46 7 71 112 000
- Website
- nosaplugs.com
About Nosa Med AB
Nosa Plugs AB (publ), a medical technology company, develops, manufactures, and sells intranasal breathing products in Sweden, Europe, North America, Oceania, and internationally. It offers NOSA smell training, a smell training medical device to improve the sense of smell for individuals with parosmia and hyposmia; NOSA odor control, which reduces bad odor; NOSA microbial control that reduces the exposure of viruses and bacteria by inhalation through the nose; NOSA Nozoil original, a moisturizing nasal spray for people suffering from dry nasal mucosa; and NOSA Cerevia, a nasal drug delivery platform for controlled administration of drugs. The company was incorporated in 2014 and is headquartered in Stockholm, Sweden.
Nosa Med AB management
2- Adrian LiljeforsChief Executive Officer · born 1989
- Karin NilssonChief Financial Officer · born 1973